Clinical trials: Huntington's Disease
Huntington Disease
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
The principal means of measuring motor impairment in Huntington disease (HD) is the Unified Huntington's Disease Rating Scale (UHDRS) total motor score, which is subjective, categorical, requires significant training to…
- Trial name
- NCT03599076
- Testing
- HD Wear
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington Disease
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed…
- Trial name
- SAVE-DH (NCT02728115)
- Testing
- Cellavita HD Lower Dose, Cellavita HD Higher dose
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- Azidus Brasil
Huntington Disease
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
- Trial name
- NCT05541627
- Testing
- AB-1001 Gene Therapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- AskBio France, SAS, a subsidiary of AskBio Inc.
Dementia, Dementia, Vascular
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members.
- Conditions
- Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease
- Trial name
- PICSI-M (NCT05596760)
- Testing
- Jumpstart Guide
- Where
- 3 sites in United States
- Volunteers
- 1,802 people
- Sponsor
- University of Washington
Huntington Disease
The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease.
- Trial name
- NAD-HD (NCT06853743)
- Testing
- Nicotinamide Riboside (NR)
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
Huntington's Disease
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's…
- Trial name
- Pre-CREST-X (NCT01411150)
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Irritable Mood, Huntington's Disease
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease.
- Trial name
- NCT02507284
- Testing
- SRX246
- Where
- 22 sites in United States
- Volunteers
- 106 people
- Sponsor
- Azevan Pharmaceuticals
Parkinson Disease, Huntington Disease
Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm
Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the…
- Trial name
- ERAMPPCI (NCT02814201)
- Testing
- SRT
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Neuromuscular Diseases, Obesity (Disorder)
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement.
- Conditions
- Neuromuscular Diseases, Obesity (Disorder), Myotonic Dystrophy 1, Myasthenic Syndrome
- Trial name
- Acti-Adult (NCT07136844)
- Testing
- Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT)
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Huntington Disease
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
- Trial name
- NCT04514367
- Testing
- ANX005
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Annexon, Inc.
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Huntington's Disease (HD)
An Extension of SKY-0515 in Participants With Huntington's Disease
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD.
- Trial name
- NCT07537075
- Testing
- SKY-0515
- Where
- 10 sites in Australia, New Zealand
- Volunteers
- 500 people
- Sponsor
- Skyhawk Therapeutics, Inc.
Huntington's Disease
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of…
- Trial name
- NCT02006472
- Testing
- Pridopidine
- Where
- 58 sites in United States, Australia and 10 more
- Volunteers
- 408 people
- Sponsor
- Prilenia
Frontotemporal Dementia, Huntington Disease
Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic…
- Conditions
- Frontotemporal Dementia, Huntington Disease, Alzheimer Disease, Semantic Dementia
- Trial name
- ISDC (NCT02819700)
- Testing
- prevalence of behavioural dysexecutive syndrome
- Where
- 2 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Parkinson Disease, Huntington Disease
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
- Trial name
- MNI-420 (NCT00970229)
- Testing
- [123I]MNI-420
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Huntington's Disease
Study of Memantine to Treat Huntington's Disease
To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).
- Trial name
- NCT00652457
- Testing
- Memantine
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jody Corey-Bloom, MD, PhD
Huntington Disease
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
This is the first clinical study of VY-HTT01, a gene therapy for early-stage Huntington's Disease (HD) patients. The primary goal of this trial is to evaluate the safety and tolerability of VY-HTT01.
- Trial name
- NCT04885114
- Testing
- Intraparenchymal rAAV1 - (mi)RNA HTT
- Sponsor
- Voyager Therapeutics
Quality of Life
Skills of Home Helpers for a Better Quality of Life for Adults With Huntington's Disease Living at Home
Huntington's disease often brings together 3 types of symptoms at one time or another of the disease during its evolution: motor, cognitive and psychiatric.
- Trial name
- COMPQUAHD (NCT04411238)
- Testing
- interview
- Volunteers
- 90 people
- Sponsor
- University Hospital, Angers